NCT07071701View on ClinicalTrials.gov

A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population

CompletedOBSERVATIONAL
Enrollment

19,267

Participants

Timeline

Start Date

July 2, 2022

Primary Completion Date

April 5, 2024

Study Completion Date

April 5, 2024

Conditions
Pneumococcal Infectious Disease
Interventions
BIOLOGICAL

23-valent pneumococcal polysaccharide vaccine

23-valent pneumococcal polysaccharide vaccine

BIOLOGICAL

Influenza vaccine

Influenza vaccine

Trial Locations (1)

Unknown

Jiangsu Provincial Center for Disease Prevention and Control, Nanjing

All Listed Sponsors
lead

Sinovac Biotech Co., Ltd

INDUSTRY